Onconetix, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Onconetix, Inc. (ONCO) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$14.45 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-13
- Onconetix, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$14.45M.
- Onconetix, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$58.99M.
- Onconetix, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$37.11M.
- Onconetix, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$13.42M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$14.45M 10-K · filed 2026-03-13 |
| 2024-12-31 | -$58.99M 10-K · filed 2026-03-13 |
| 2023-12-31 | -$37.11M 10-K · filed 2025-06-02 |
| 2022-12-31 | -$13.42M 10-K · filed 2024-04-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |